New Dopamine Agonist Pramipexole Improves Parkinsonism and Depression in Parkinson's Disease
HiroshimaJMedSci_60_79.pdf 159 KB
Previous studies have shown that pramipexole might have the potential to improve depressive symptoms in patients with Parkinson's disease. To provide more evidence, in five Japanese patients at Hoehn & Yahr stage 1-3 we evaluated the Unified Parkinson's Disease Rating Scale (UPDRS), Hamilton Depression Rating Scale (HAMD) and Montgomery Asberg Depression Rating Scale (MADRS) at our hospital. After the pramipexole treatment, each total score of UPDRS, HAMD and MADRS significantly decreased compared with that before the treatment. Our data indicate that pramipexole improves depressive symptoms in patients with Parkinson's disease.
Hiroshima Journal of Medical Sciences
|date of issued||
Hiroshima University Medical Press
Departmental Bulletin Paper
Departmental Bulletin Papers
(c) Hiroshima University Medical Press.
Graduate School of Biomedical Science
Last 12 months's access : ? times
Last 12 months's DL: ? times
This month's access: ? times
This month's DL: ? times